Ultroid Technologies, Inc.
Quick, Easy, Painless and Proven Solution for HD

15
Dec

Former Johnson & Johnson Senior Executive Wycliffe (Cliff) McIntosh to Lead Innovative Medical Device Company
St. Petersburg, FL Dec. 15, 2009 — Ultroid® Technologies, Inc., a leader in non-invasive, low cost, micro current technologies announced today that Wycliffe (Cliff) McIntosh has joined the company to serve as Chief Executive Officer.

Cliff McIntosh brings significant medical device experience to Ultroid Technologies, Inc. Most recently, he was President of the highly successful Johnson & Johnson (JNJ) Diabetes Institute where he created a best in class global organization dedicated to training health care professionals. His responsibilities also included successful commercial leadership roles in international sales & marketing, finance, strategic planning and general management spanning over 24 years with the company.

“We are excited that Cliff has joined the Ultroid Technologies, Inc. executive team,” said Dr. Howard Howell, Board Chairman of Ultroid Technologies, Inc., “and we are looking forward to Cliff’s leadership, expertise, and years of international experience to complete Ultroid’s global marketing strategy. He brings a broad range of leadership qualities, an in depth understanding of medical devices and a strong commitment to excellence. These attributes, along with his compassion to help people, make him the perfect CEO to lead the Ultroid team in its rapid growth and success in the national and international medical device arena.”

Over the past 15 years, Cliff held several commercial leadership positions with Johnson & Johnson (JNJ). He was an International Vice President and directly responsible for several diabetes care medical device companies in Europe, Middle East & Africa and Asia/Pacific, where he led consumer and professional marketing development, launched innovative new products, achieved market share leadership and developed high performance teams across many regions of the world. As a past Board member of the European Diagnostic Manufacturing Association and the British In-Vitro Diagnostic Association, he led several EU initiatives across Europe addressing product safety. Cliff is a graduate of Fordham University and holds several leadership certificates from prestigious institutions including the University of Pennsylvania.

“I am extremely excited to join the Ultroid team at this time in the company’s evolution. We have a unique opportunity to create a new standard of care for people suffering from hemorrhoid disease and make a tremendous impact on their quality of life. I look forward to the challenges in building commercial value and leveraging the great technology.”

About Ultroid Technologies, Inc.

Ultroid Technologies, Inc. is a leader in non-invasive, low cost, micro current technologies in the United States. Its flagship product is the Ultroid® Hemorrhoid Management System, a non-invasive, painless, and low cost treatment. This procedure for the treatment of hemorrhoidal disease (HD) is applicable for all four grades of internal hemorrhoids. The Ultroid Procedure is effective in over 40,000 procedures and has over a 95% effective rate with no reported complications. The Ultroid System replaces over-the-counter creams and painful surgeries by providing a quick, painless, and permanent solution without interrupting daily activities.

The Company’s website is www.Ultroid.com. The brand names referenced in this press release are trademarks of Ultroid Technologies, Inc. its affiliated companies, customers, or other third parties. The company markets and manufactures the Ultroid Hemorrhoid Management System.

Safe Harbor Statements
This press release may contain forward-looking statements reflecting management’s current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company’s filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:

Ultroid Technologies, Inc., St. Petersburg
Mike Wodstrchill, 877-858-0555
Fax: 727-898-0716
www.Ultroid.com

Category : UltroidNews